prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - грипен вирус повърхностните антигени (хемаглутинин и невраминидазния) на щам a/Виетнам/1194/2004 (Н5n1) - influenza, human; immunization; disease outbreaks - Ваксини - Активна имунизация срещу подтип h5n1 на вируса на грипа А. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - Ваксини - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - Ваксини - active immunisation against h5 subtype of influenza a virus.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
vancocin cp lg powder for solution for infusion
Чайкафарма Висококачествените лекарства АД - Ванкомицин - lg powder for solution for infusion
vancomycin-mip 500 mg powder for solution for infusion
mip pharma gmbh - Ванкомицин - 500 mg powder for solution for infusion
vancomycin-mip 1000 mg powder for solution for infusion
mip pharma gmbh - Ванкомицин - 1000 mg powder for solution for infusion
vancomycin hospira 500 mg powder for concetrate for solution for infusion
hospira uk ltd. - Ванкомицин - 500 mg powder for concetrate for solution for infusion
vancomycin hospira 1000 mg powder for concentrate for solution for infusion
hospira uk ltd. - Ванкомицин - 1000 mg powder for concentrate for solution for infusion
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - ресусортен грипен вирус (жив атенюиран) на следния щам: щам a / vietnam / 1203/2004 (h5n1) - Грип, Човек - Ваксини - Профилактика на грип при официално обявена пандемична ситуация при деца и юноши на възраст от 12 месеца до 18 години. Ваксина срещу пандемичен грип h5n1 АстраЗенека трябва да се използва в съответствие с официалните насоки.